BACKGROUND Routine apolipoprotein (apo) measurements for cardiovascular disease (CVD) are restricted to apoA-I
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To estimate effects of apoC-III synthesis inhibition, for each subject, measurements at day 1 (baseline) and means of measurements at days 57 and 92 (under treatment) were log-transformed, and the change from Pechlaner et al.
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When investigating whether apoC-III, apoC-II, and apoE could improve on traditional risk factors in 10-year cardiovascular risk prediction (Online Table 2 ), no significant change in the c-index was found; however, a significantly positive net reclassification index indicated that 12.3% of subjects could be more appropriately classified into the clinically relevant risk categories of 0.0% to 5.0%, 5.0% to 7.5%, or more than 7.5% when including apolipoproteins.
INTERRELATIONSHIPS BETWEEN APOLIPOPROTEINS.
Correlations among apolipoproteins and standard lipid measures are shown in Hazard ratio (95% CI) P value
Hazard ratio (95% CI) P value Hazard Ratio for a One-SD Higher Plasma Concentration (95% Confidence Interval)
Hazard ratio (95% CI) P value
Hazard ratio (95% CI) P value As in model 1, with additional adjustment for diabetes, systolic blood pressure, and smoking. Pechlaner et al.
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T r i g l y c e r i d e s
Results are adjusted for age, sex, and statin therapy. Tile color codes for direction and magnitude of correlation, whereas tile text gives its sign and the first 2 decimal digits. Variables are arranged by similarity, as shown in the right-hand dendrogram. Only significant correlations are shown. Clustering gave rise to several groups of highly intercorrelated variables. High-level clusters were characterized by more extensive correlations with apoA-I (top right region) or with apoB-100 (bottom left region), with the latter containing subclusters likely representing VLDL (including apoC-III, apoC-II, apoE, TG, non-HDL-C, and HDL-C) and LDL (including apoB-100 and LDL-C). VLDL ¼ very-low-density lipoprotein; other abbreviations as in Figure 1 . Figures 6A and 6B , bottom row) and, to a lesser extent, upon adjustment for apoE (Online Figure 6C ). This is consistent with the notion that apoC-II and apoC-III were more strongly correlated with total cholesterol, non-HDL-C, and TGs than apoE (Online Figure 4) . messenger RNA, termed volanesorsen, was used to lower plasma apoC-III levels (2,3). We obtained plasma samples from cohorts of these studies that had varying degrees of marked hypertriglyceridemia before and after volanesorsen therapy, and measured apolipoproteins and selected lipids by MRM-MS. As expected, inhibition of hepatic apoC-III synthesis substantially reduced plasma apoC-III levels in all subjects (mean decreases >75%). Remarkably, this was associated with w50% decreases in both apoC-II and apoE, and modest increases in apoA-I, apoA-II, and apoM, whereas levels of apoB-100 did not change, except in the 3 subjects with familial chylomicronemia syndrome (FCS) (IONIS1), who experienced a marked decrease in TGs ( Figure 5A) . Consistent with this, apoC-III inhibition lowered plasma concentrations of TAG as expected, but also lowered diacylglycerols (DAGs) ( Figure 5B). Base adjustment consisted of adjustment for age, sex, and statin therapy and is shown for the significant apolipoproteins only in the first column (as in Figure 1 ).
Additional adjustment for apoC-II, apoC-III, or apoE is shown in the other 3 columns, respectively. Note that apoB-100 loses its association with incident CVD upon adjustment for any of the 3 VLDL-associated apolipoproteins. Abbreviations as in Figures 1 and 2 .
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clearance by an LPL-independent pathway (2, 22, 23) .
This is thought to be due to inhibiting hepatic clearance of TRL lipoproteins mediated by LDLR or LRP-1 (18, 21, 23) . Thus, it is now apparent that apoC-III regulates TRL metabolism by both an LPL-dependent and LPL-independent pathway, and is thus a central regulator of plasma TG levels (2, 7, 18, 22) .
ApoC-II, apoC-III, and apoE were associated with obesity, hypertension, impaired glucose metabolism, and most strongly with lipid parameters (Online The reduction in apoC-III levels was profound, leading to >75% decreases at the dose of antisense used. This was associated not only with marked reductions in plasma TGs of w70%, but there were nearly 50% decreases in both apoC-II and apoE. These changes are consistent with lowering of VLDL and remnant lipoproteins (7, 21) , and are in line with observations after apoC-III inhibition in mice, nonhuman primates, and humans (2, 3, 29) . However, the disparity between the extent of reduction in apoC-III, apoC-II, and apoE suggests some measures of independence in the metabolism of these 3 apolipoproteins, and it is well known that they may reside on other lipoproteins, such as HDL (30) . Indeed, the observed increase in apoA-I, apoA-II, and apoM is consistent with the reported rise of HDL-C following apoC-III inhibition (3, 29) and lower HDL-C levels in apoC-III transgenic mice (31) . A potential mechanistic explanation is reduced exchange of HDL-C with VLDL-TG mediated via cholesterol ester transfer protein (CETP) (7, 29) . Notably, apoM has been reported to mark an HDL subpopulation that stimulates particularly efficient cholesterol efflux (32) .
Although apoC-III delays clearance of VLDL remnants that contain apoB-100, apoC-III inhibition by volanesorsen did not reduce total apoB-100 levels.
This may be explained by the fact that although VLDL-apoB levels were decreased (2,3), there was a small compensatory increase in LDL. This was likely in part due to CETP-mediated remodeling of the lipoprotein cholesterol content (3), increased conversion of VLDL to LDL mediated by LPL, or changes in so-called metabolic channeling of VLDL to small dense LDL (7, 14, 15, 18) . Importantly, total apoB levels did not increase or were slightly decreased in the volanesorsen-treated hypertriglyceridemic subjects who were on other hypolipidemic agents (3).
This would explain why only 16% lower apoB-100 levels were reported in carriers of apoC-III loss-offunction mutations with normal TG levels (13), although a recent report of such subjects did not find lower LDL levels (25) . Following apoC-III inhibition, TAGs and DAGs were decreased ( Figure 5B ).
Although the former is expected, the latter is however, <10% of participants in the Bruneck study were on statin therapy, and exclusion of subjects on statin therapy yielded similar results (Online Figure 3) .
Future studies could extend the present study by measuring apolipoproteins within lipoprotein subfractions. Our findings of strong associations with apolipoproteins, such as apoL-I and apoH, for which published data are lacking, should be considered hypothesis-generating and deserving of further study.
CONCLUSIONS
Our data provide strong epidemiological support to the concept that TRLs contribute to atherosclerosis. Pechlaner et al. Pechlaner et al.
